利索-全球专利检索

  1. 登录
  2. 注册
发明公开
CN109280087A 一种双靶向转换受体、编码基因、重组表达载体、抗肿瘤NK细胞及其制备方法、应用 有权

一种双靶向转换受体、编码基因、重组表达载体、抗肿瘤NK细胞及其制备方法、应用
摘要：
本发明涉及一种双靶向转换受体、编码基因、重组表达载体、抗肿瘤NK细胞及其制备方法、应用，属于肿瘤免疫细胞治疗技术领域。本发明的双靶向转换受体分为两段，由PD1胞外段（1-170aa），DAP10胞外、跨膜及胞内段（19-93aa）组成的第一受体和由NKG2D全长段（1-216aa）组成的第二受体，两者在细胞内可以快速的结合，形成双靶向转换受体，该受体可以增强NK细胞对于胃癌细胞的抗肿瘤免疫效应。使用双靶向转换受体改造的Ha-DTCR-NK92与NK92细胞相比，对于胃癌细胞MGC-803细胞的细胞毒性增加了约3倍，而对于胃癌细胞SGC-7901细胞的细胞毒性增加了约9倍。
摘要（英）：

The invention relates to a double-target conversion receptor, a coding gene, a recombinant expression vector, an anti-tumor NK cell, and a preparation method and application of the anti-tumor NK cell,and belongs to the technical field of tumor immune cell treatment. The double-target conversion receptor is divided into two sections which comprise a first receptor and a second receptor, wherein the first receptor consists of a PD1 extracellular domain (1-170aa) and a DPA10 extracellular, transmembrane and intracellular domain (19-93aa), and the second receptor consists of an NKG2D full-lengthdomain (1-216aa). The two receptors can be rapidly combined in cells to form the double-targetconversion receptor which can enhance the anti-tumor immune effect of NK cells on gastric cancer cells. Compared with NK92 cells, Ha-DTCR-NK92 modified by using the double-target conversion receptor has the advantages that cytotoxicity on gastric cancer MGC-803 cells is increased by about 3 times, and cytotoxicity on gastric cancer SGC-7901 cells is increased by about 9 times.

公开/授权文献
0/0